Mysuru: With green signal from the government, Jubilant Generics, the pharmaceutical company, which made Nanjangud a COVID-19 hotspot, is all set to resume operations.
It may be recalled that Jubliant Life Sciences, the parent company of Jubilant Generics has tied up with US drug giant Gilead to manufacture and sell Remdisvir, which is believed to offer an efficient treatment for COVID-19.
"For manufacturing ‘Remdesivir’ the work on modification of the plant to supply the product has to begin immediately. In view of this extreme urgency, it is critical to resume and normalise operations at the Jubilant Generics, Nanjangud plant immediately. Jubilant also manufactures Azithromycin Dihydrate and Azithromycin Monohydrate that are used as the first line of treatment for COVID-19," a letter to the government by the company read.
Keeping this in mind, the government has given its nod to resume operations and as per sources the operations will commence in a week or two.
It can be recalled that Patient 52 was an employee of Jubilant Generics. He was identified as source of the infection in Nanjangud cluster.
© Copyright NewsKarnataka 2020 . All Rights Reserved.
Website maintained by Technixserv